Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
Journal of Infection and Public Health2021Vol. 14(6), pp. 740–748
Citations Over TimeTop 10% of 2021 papers
Tejas Patel, Parvati B. Patel, Manish Barvaliya, Manoj Kumar Saurabh, Hira Lal Bhalla, Prem Parkash Khosla
Abstract
There is no benefit of the addition of lopinavir-ritonavir to the standard care in COVID-19 patients.
Related Papers
- → Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019(2020)39 cited
- → Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir(2009)27 cited
- → Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice‐Daily to Once‐Daily Therapy(2007)17 cited
- PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.(2015)
- → Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir(2012)3 cited